/NNBP

NNBP Stock - Nanobac Pharmaceuticals, Incorporated

Q: What is the analyst price target for NNBP?

Analyst price target information is not currently available for NNBP.

Q: What is NNBP's market cap?

Market capitalization information is not currently available for NNBP.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for NNBP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2003

FY2004

FY2005

FY2006

FY2007

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-35.70

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2007	FY2006	FY2005	FY2004	FY2003
Revenue	$17,621	$225,086	$656,802	$358,361	$482,815
Gross Profit	$3,102	$145,281	$427,356	$257,891	$149,693
Gross Margin	17.6%	64.5%	65.1%	72.0%	31.0%
Operating Income	$4.91M	$4.81M	$2.84M	$7.60M	$2.70M
Net Income	$-6,576,111	$-4,973,353	$-3,687,337	$-7,874,778	$-3,699,491
Net Margin	-37319.7%	-2209.5%	-561.4%	-2197.4%	-766.2%
EPS	$0.00	$-0.02	$-0.02	$-0.05	$-0.05

Company Overview

Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.

Frequently Asked Questions about NNBP

What is NNBP's current stock price?

Nanobac Pharmaceuticals, Incorporated (NNBP) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for NNBP?

No analyst price targets are currently available for this stock.

What sector is Nanobac Pharmaceuticals, Incorporated in?

Nanobac Pharmaceuticals, Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is NNBP's market cap?

Nanobac Pharmaceuticals, Incorporated has a market capitalization of $0.00 billion, making it a small-cap company.

Does NNBP pay dividends?

No, Nanobac Pharmaceuticals, Incorporated does not currently pay a dividend to shareholders.